Speech-Language Pathologists in Mt Zion, IL Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Rachael Connelly, SPEECH PATHOLOGIST Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Mt Zion Elementary, 725 W Main St, Mt Zion, IL 62549 Phone: 217-864-3631

Mrs. Cassie E Mavis, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1521 Hunters View Dr, Mt Zion, IL 62549 Phone: 217-972-9720

Courtney Trudeau Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1615 Sherwood Ct, Mt Zion, IL 62549 Phone: 217-855-9563

Mrs. Morgan Nicole Holst, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 725 W Main St, Mt Zion, IL 62549 Phone: 217-864-9435

News Archive

U.S. Physical Therapy net income for second-quarter 2010 increases 23% to $4.5 million

U.S. Physical Therapy, Inc., a national operator of outpatient physical therapy clinics, today reported results for the second quarter and six months ended June 30, 2010.

Another bird flu death in Indonesia pushes death toll up to 108

Indonesia's health ministry has announced that a three-year-old boy from Java has died from bird flu pushing the country's death toll up to 108.

Scientists unravel immune cascade that drives tissue damage, complications in chlamydia infections

Closing a critical gap in knowledge, Harvard Medical School scientists have unraveled the immune cascade that fuels tissue damage and disease development in chlamydia infection-;the most common sexually transmitted disease in the United States.

Interleukin, U-M School of Dentistry complete enrollment in PST Genetic Test study

The University of Michigan School of Dentistry and Interleukin Genetics, Inc. announced today the completion of patient enrollment for a landmark clinical study using Interleukin's PST Genetic Test to determine if dental patients can be risk-stratified to guide frequency of preventive dental visits and reduce the adverse outcomes of periodontal disease progression, such as tooth loss.

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

Read more Medical News

› Verified 6 days ago